Literature DB >> 23542057

Lesion HLA-F expression is irrelevant to prognosis for patients with gastric cancer.

Jian-Gang Zhang1, Xia Zhang, Aifen Lin, Wei-Hua Yan.   

Abstract

Alteration of human leukocyte antigen (HLA) antigen expression has been supposed to play critical roles in progression of malignancies. However, clinical significance of the non-classical HLA class I antigen HLA-F remains largely unknown. In this study, HLA-F expression in 277 primary gastric cancer (GC) lesions was analyzed by immunohistochemistry. Data revealed that HLA-F expression was observed in 71.1% (197/277) of the GC lesions. Lesion HLA-F expression was unrelated to the clinicoparameters such as gender, age, depth of tumor invasion and disease stage. Survival analysis revealed that HLA-F expression in GC lesion was unrelated to patient prognosis (p=0.190). The mean overall survival time (MOS) for lesion HLA-F negative and positive patients was 11.3 months (95% CI: 9.3-13.3) and 13.9 months (95% CI: 10.5-17.3), respectively. In conclusion, our study provided the evidence that HLA-F expression was unrelated to prognosis for patients with gastric cancer.
Copyright © 2013 American Society for Histocompatibility and Immunogenetics. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23542057     DOI: 10.1016/j.humimm.2013.03.002

Source DB:  PubMed          Journal:  Hum Immunol        ISSN: 0198-8859            Impact factor:   2.850


  5 in total

1.  HLA-DQB1*03 genotype and perioperative blood transfusion are not conducive to the prognosis of patients with gastric cancer.

Authors:  Shen-Kang Zhou; Lei-Lei Yang; Rui Chen; Yong Lu; Yong-Hua Zheng
Journal:  J Clin Lab Anal       Date:  2018-04-18       Impact factor: 2.352

2.  Lesion human leukocyte antigen-F expression is associated with a poor prognosis in patients with hepatocellular carcinoma.

Authors:  Yongfu Xu; Haixiong Han; Fabiao Zhang; Shangdong Lv; Zhengyu Li; Zheping Fang
Journal:  Oncol Lett       Date:  2014-11-07       Impact factor: 2.967

3.  HLA-F*01:01 presents peptides with N-terminal flexibility and a preferred length of 16 residues.

Authors:  Gia-Gia T Hò; Funmilola J Heinen; Trevor Huyton; Rainer Blasczyk; Christina Bade-Döding
Journal:  Immunogenetics       Date:  2019-04-02       Impact factor: 2.846

4.  HLA and proteasome expression body map.

Authors:  Sebastian Boegel; Martin Löwer; Thomas Bukur; Patrick Sorn; John C Castle; Ugur Sahin
Journal:  BMC Med Genomics       Date:  2018-03-27       Impact factor: 3.063

5.  HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment.

Authors:  Franziska M Wuerfel; Hanna Huebner; Lothar Häberle; Paul Gass; Alexander Hein; Sebastian M Jud; Carolin C Hack; Marius Wunderle; Rüdiger Schulz-Wendtland; Ramona Erber; Arndt Hartmann; Arif B Ekici; Matthias W Beckmann; Peter A Fasching; Matthias Ruebner
Journal:  Sci Rep       Date:  2020-09-25       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.